In a conversation with Pharmaceutical Executive, Morten Graugaard, CEO, Orbis Medicines, discussed FDA’s approval of Icotyde ...

The firm will deliver SGT-212 to patients' brains and intravenously to try to restore frataxin levels and diminish ...

VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

A majority of the Supreme Court justices seemed skeptical of the Trump administration's argument on birthright citizenship Wednesday and appeared ready to rule in favor of upholding automatic ...

The European panel has expanded delivery options for multiple myeloma by approving a subcutaneous (SC) option for a key anti‑CD38 myeloma therapy. At its March 2026 meeting, the European Medicines ...

Covalent-organic frameworks (COFs) and metal-organic frameworks (MOFs) have been a promising carrier for drug delivery because of excellent biocompatibility, developed porous structure and sufficient ...

Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million. OrbiMed ...

China’s BrightGene has served up a slice of early-stage data to remind everyone it has a horse in the oral obesity race. The Suzhou-based biotech has been evaluating its dual GLP-1/GIP agonist, dubbed ...

Virginia Allen is a senior news producer for The Daily Signal and host of "The Daily Signal Podcast" and "Problematic Women." Send an email to Virginia. Faith is a central part of the Trump ...

This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk is expecting more clinical data for ...

Treasury Secretary Scott Bessent on Sunday defended strikes on Iran’s infrastructure since the U.S. and Israel began their joint war against the country in February, saying “sometimes you have to ...